| |
Low Progressors*
|
High Progressors*
|
Comparison
|
SRC
|
|---|
|
Cohort characteristics
|
(n= 29)
|
(n= 29)
|
z
|
P
$
|
rho
|
P
|
|---|
|
Demographic
| | | | | | |
|
Female, no. (%)
|
22 (76%)
|
15 (52%)
|
3.66
|
0.100†
|
-
|
NA
|
|
Age, mean ± SD, years
|
52 ± 10
|
55 ± 12
|
0.97
|
0.334‡
|
-
|
NA
|
|
Disease duration, days
|
260 (169, 412)
|
242 (146, 384)
|
-0.59
|
0.555
|
-
|
NA
|
|
DAS28
|
5.1 (4.0, 6.1)
|
6.2 (4.8, 6.8)
|
1.73
|
0.083
|
-
|
NA
|
|
HAQ
|
1.3 (0.9, 2.0)
|
1.5 (1.0, 2.3)
|
0.90
|
0.370
|
-
|
NA
|
|
No. DMARDsφ
|
2 (1, 2)
|
2 (2, 3)
|
1.81
|
0.070
|
-
|
NA
|
|
MTX, no. (%)φ
|
8 (28)
|
21 (72)
|
11.66
|
0.001†
|
-
|
NA
|
|
Traditional measures
| | | | | | |
|
Total SHS
|
3 (0, 8)
|
16 (6, 28)
|
4.09
|
< 0.001
|
0.51
|
< 0.001
|
|
ESR, mm/hour
|
19 (11, 39)
|
34 (20, 50)
|
2.33
|
0.020
|
0.35
|
0.008
|
|
CRP mg/L
|
8 (5, 20)
|
34 (15, 65)
|
3.42
|
< 0.001
|
0.46
|
< 0.001
|
|
RF positive, no. (%)
|
19 (66%)
|
26 (90%)
|
4.86
|
0.056†
|
0.47
|
< 0.001
|
|
Anti-CCP +ve, no. (%)φ
|
14 (48%)
|
26 (90%)
|
11.60
|
0.001†
|
0.23
|
0.077
|
|
SJC
|
6 (2, 12)
|
10 (5, 15)
|
1.80
|
0.072
|
0.19
|
0.145
|
|
TJC
|
14 (5, 18)
|
15 (7, 18)
|
0.47
|
0.640
|
0.06
|
0.675
|
|
CGA on VAS, mm
|
24 (10, 57)
|
54 (38, 68)
|
2.48
|
0.013
|
0.34
|
0.010
|
|
PGA on VAS, mm
|
39 (27, 48)
|
47 (24, 65)
|
0.53
|
0.600
|
0.10
|
0.447
|
|
Biomarkers
| | | | | | |
|
MMP-3, ng/mL
|
51 (32, 86)
|
137 (86, 359)
|
3.83
|
< 0.001
|
0.46
|
< 0.001
|
|
CTX-II, μg/mmol
|
0.14 (0.08, 0.25)
|
0.36 (0.19, 0.57)
|
3.40
|
< 0.001
|
0.40
|
0.003
|
|
COMP, U/L
|
10 (8, 11)
|
13 (11, 16)
|
3.27
|
0.001
|
0.39
|
0.003
|
|
TIMP-1, ng/mL
|
647 (466, 719)
|
817 (669, 902)
|
2.34
|
0.019
|
0.29
|
0.029
|
- *Except where indicated otherwise, values are median (25th and 75th percentiles). $Determined by Mann Whitney U test unless indicated otherwise. †Determined by Fisher's two-sided exact test. ‡Determined by Student's t test. φ Value taken at 8.2-year follow-up visit.
- Anti-CCP, anti-cyclic citrullinated peptide; CGA, clinician's global assessment; COMP, cartilage oligomeric matrix protein; CRP, C-reactive protein; CTX-II, C-telopeptide of type II collagen; DAS, disease activity score; DMARD, disease-modifying anti-rheumatic drug; ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; MMP-3, matrix metalloproteinase-3; MTX, methotrexate; NA, not applicable; NS, not significant; PGA, patient's global assessment; RF, rheumatoid factor; SD, standard deviation; SHS, van der Heijde modified Sharp score; SJC, swollen joint count; SRC, Spearman's rank correlation; TIMP-1, tissue inhibitor of metalloproteinase 1; TJC, tender joint count; VAS, visual analogue score.
